Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.

Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7608025 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2072 (Electronic) Linking ISSN: 00333158 NLM ISO Abbreviation: Psychopharmacology (Berl) Subsets: MEDLINE

Original Publication: Berlin, New York, Springer-Verlag.

Depression*/drug therapy ; Venlafaxine Hydrochloride*/therapeutic use; Humans ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Desvenlafaxine Succinate/therapeutic use ; Norepinephrine ; Reference Values ; Serotonin

Introduction: The selective serotonin and norepinephrine reuptake inhibitor venlafaxine is among the most prescribed antidepressant drugs worldwide and, according to guidelines, its dose titration should be guided by drug-level monitoring of its active moiety (AM) which consists of venlafaxine (VEN) plus active metabolite O-desmethylvenlafaxine (ODV). This indication of therapeutic drug monitoring (TDM), however, assumes a clear concentration/effect relationship for a drug, which for VEN has not been systematically explored yet.
Objectives: We performed a systematic review and meta-analysis to investigate the relationship between blood levels, efficacy, and adverse reactions in order to suggest an optimal target concentration range for VEN oral formulations for the treatment of depression.
Methods: Four databases (MEDLINE (PubMed), PsycINFO, Web of Science Core Collection, and Cochrane Library) were systematically searched in March 2022 for relevant articles according to a previously published protocol. Reviewers independently screened references and performed data extraction and critical appraisal.
Results: High-quality randomized controlled trials investigating concentration/efficacy relationships and studies using a placebo lead-in phase were not found. Sixty-eight articles, consisting mostly of naturalistic TDM studies or small noncontrolled studies, met the eligibility criteria. Of them, five cohort studies reported a positive correlation between blood levels and antidepressant effects after VEN treatment. Our meta-analyses showed (i) higher AM and (ii) higher ODV concentrations in patients responding to VEN treatment when compared to non-responders (n = 360, k = 5). AM concentration-dependent occurrence of tremor was reported in one study. We found a linear relationship between daily dose and AM concentration within guideline recommended doses (75-225 mg/day). The population-based concentration ranges (25-75% interquartile) among 11 studies (n = 3200) using flexible dosing were (i) 225-450 ng/ml for the AM and (ii) 144-302 ng/ml for ODV. One PET study reported an occupancy of 80% serotonin transporters for ODV serum levels above 85 ng/ml. Based on our findings, we propose a therapeutic reference range for AM of 140-600 ng/ml.
Conclusion: VEN TDM within a range of 140 to 600 ng/ml (AM) will increase the probability of response in nonresponders. A titration within the proposed reference range is recommended in case of non-response at lower drug concentrations as a consequence of VEN's dual mechanism of action via combined serotonin and norepinephrine reuptake inhibition. Drug titration towards higher concentrations will, however, increase the risk for ADRs, in particular with supratherapeutic drug concentrations.
(© 2023. The Author(s).)

BMC Psychiatry. 2017 Jun 19;17(1):222. (PMID: 28629442)
World J Biol Psychiatry. 2022 Mar;23(3):183-190. (PMID: 34096828)
Int J Geriatr Psychiatry. 2007 Dec;22(12):1247-54. (PMID: 17562523)
Nord J Psychiatry. 2017 Apr;71(3):230-237. (PMID: 28079463)
Ther Drug Monit. 2021 Oct 1;43(5):672-680. (PMID: 33560096)
Int J Geriatr Psychiatry. 2006 Jun;21(6):542-9. (PMID: 16642541)
Eur J Clin Pharmacol. 2004 Jul;60(5):329-36. (PMID: 15168101)
Pharmacopsychiatry. 2014 Jul;47(4-5):174-9. (PMID: 25054625)
Synapse. 2018 Mar;72(3):. (PMID: 29216407)
J Psychopharmacol. 2010 Apr;24(4):537-46. (PMID: 18832427)
Int Clin Psychopharmacol. 2019 Sep;34(5):241-246. (PMID: 31094902)
J Clin Psychopharmacol. 2000 Oct;20(5):538-43. (PMID: 11001238)
Br J Clin Pharmacol. 1996 Feb;41(2):149-56. (PMID: 8838442)
Can J Psychiatry. 2016 Sep;61(9):540-60. (PMID: 27486148)
J Psychopharmacol. 2020 Oct;34(10):1105-1111. (PMID: 32669065)
Ther Drug Monit. 2016 Feb;38(1):127-34. (PMID: 26418700)
Psychopharmacology (Berl). 2022 Nov;239(11):3377-3391. (PMID: 36195732)
Psychother Psychosom. 2022;91(2):84-93. (PMID: 34965534)
Eur Neuropsychopharmacol. 2016 Apr;26(4):705-16. (PMID: 26899588)
Int Clin Psychopharmacol. 2018 Nov;33(6):322-329. (PMID: 30028351)
J Clin Psychopharmacol. 2021 Jan/Feb 01;41(1):62-66. (PMID: 33208708)
World J Biol Psychiatry. 2021 Oct;22(8):561-628. (PMID: 33977870)
J Clin Psychiatry. 2015 Jan;76(1):25-31. (PMID: 25188033)
Ther Drug Monit. 2021 Oct 1;43(5):681-687. (PMID: 33306568)
Pharmacopsychiatry. 2016 Sep;49(5):186-190. (PMID: 27101231)
J Clin Psychopharmacol. 2020 Mar/Apr;40(2):137-144. (PMID: 32134850)
Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):298-302. (PMID: 28397349)
Am J Psychiatry. 2004 May;161(5):826-35. (PMID: 15121647)
Int Clin Psychopharmacol. 2014 Jul;29(4):206-11. (PMID: 24374906)
J Clin Psychopharmacol. 2007 Feb;27(1):71-5. (PMID: 17224717)
Nord J Psychiatry. 2012 Jun;66(3):147-54. (PMID: 22458638)
Lancet. 2018 Apr 7;391(10128):1357-1366. (PMID: 29477251)
J Psychopharmacol. 2002 Dec;16(4):369-72. (PMID: 12503838)
Pharmacopsychiatry. 2019 Feb;52(2):78-83. (PMID: 29458223)
Pharmacopsychiatry. 2012 Sep;45(6):229-35. (PMID: 22426847)
J Clin Psychiatry. 2010 Nov;71(11):1482-7. (PMID: 20441720)
Eur J Clin Pharmacol. 2002 Aug;58(5):323-31. (PMID: 12185556)
Lancet Psychiatry. 2019 Jul;6(7):601-609. (PMID: 31178367)
Front Psychiatry. 2022 Feb 21;13:826138. (PMID: 35264987)
PLoS Med. 2021 Mar 29;18(3):e1003583. (PMID: 33780438)
Front Psychiatry. 2021 Nov 24;12:787043. (PMID: 34899439)
J Clin Pharm Ther. 2006 Oct;31(5):493-502. (PMID: 16958828)
Ther Drug Monit. 2000 Apr;22(2):202-8. (PMID: 10774634)
World J Biol Psychiatry. 2019 Jan;20(1):2-16. (PMID: 30526182)
Pharmacopsychiatry. 2003 Jan;36(1):3-6. (PMID: 12649767)
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):278-285. (PMID: 30649319)
Pharmacopsychiatry. 2021 May;54(3):117-125. (PMID: 33291155)
J Affect Disord. 2018 Feb;227:506-511. (PMID: 29156365)
Int Clin Psychopharmacol. 2019 Mar;34(2):93-100. (PMID: 30557209)
Pharmacopsychiatry. 2018 Jan;51(1-02):9-62. (PMID: 28910830)
J Clin Psychopharmacol. 2018 Oct;38(5):498-501. (PMID: 30102628)
Hum Psychopharmacol. 2020 May;35(3):e2733. (PMID: 32239743)
Ther Drug Monit. 2021 Apr 1;43(2):286-291. (PMID: 32910098)
Biol Psychiatry. 2007 Dec 15;62(12):1371-9. (PMID: 17825800)
J Clin Psychopharmacol. 2003 Dec;23(6):568-75. (PMID: 14624187)
Pharmacopsychiatry. 2019 Jan;52(1):38-43. (PMID: 29466824)
Ther Drug Monit. 2002 Aug;24(4):545-53. (PMID: 12142641)
Neuropsychopharmacology. 1999 May;20(5):480-90. (PMID: 10192828)
Front Psychiatry. 2022 Oct 17;13:972141. (PMID: 36325531)
Eur J Clin Pharmacol. 2014 Aug;70(8):933-40. (PMID: 24858822)
Eur J Clin Pharmacol. 2019 Aug;75(8):1109-1116. (PMID: 30968172)
Ther Drug Monit. 2011 Feb;33(1):14-20. (PMID: 21099743)
Eur J Clin Pharmacol. 2008 May;64(5):483-7. (PMID: 18214456)
Drug Metab Pharmacokinet. 2012;27(1):55-67. (PMID: 22185816)
J Neural Transm (Vienna). 2015 May;122(5):721-9. (PMID: 25257248)
Int J Neuropsychopharmacol. 2022 Apr 19;25(4):283-292. (PMID: 34958348)
Clin Pharmacokinet. 2018 Jun;57(6):729-737. (PMID: 28866861)
J Clin Psychopharmacol. 2011 Feb;31(1):92-7. (PMID: 21192150)

Keywords: Antidepressant; Depression; Venlafaxine

0 (Antidepressive Agents)
ZB22ENF0XR (Desvenlafaxine Succinate)
X4W3ENH1CV (Norepinephrine)
333DO1RDJY (Serotonin)
7D7RX5A8MO (Venlafaxine Hydrochloride)

Date Created: 20231019 Date Completed: 20240124 Latest Revision: 20241023

20250114

PMC10806172

10.1007/s00213-023-06484-7

37857898